DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Prostate Cancer | Access & Reimbursement | Detailed, Expanded Analysis (Brazil/Mexico)

Prostate Cancer | Access & Reimbursement | Detailed, Expanded Analysis (Brazil/Mexico)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Tens of thousands of Brazilian and Mexican men are diagnosed with prostate cancer every year. In recent years, there have been multiple clinical advances in the field, with new therapies offering longer survival times, milder safety and tolerability profiles and improved quality of life over existing treatments. However, those achievements have come with a hefty price tag and while the new therapies have become the standard of care in the United States and Europe, Brazil’s and Mexico’s cost-constrained markets are still struggling to widely adopt them in their medical practice. The future will bring more new prostate cancer therapies, and while prescribers are eager to use emerging agents, limited budgets will restrict their uptake and, in an increasingly competitive market, only drugs that meet both clinical and economic expectations will succeed. This A&R analysis provides key insights for navigating the prostate cancer market in Brazil and Mexico, uncovering payer and prescriber expectations in each country.

Table of contents

  • Detailed, Expanded Analysis (Brazil/Mexico)
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for New Prostate Cancer Therapies in Brazil and Mexico
    • Successes and Stumbles
      • Successes Among Prostate Cancer Therapies in Brazil and Mexico
      • Stumbles Among Prostate Cancer Therapies in Brazil and Mexico
      • Brazil: Coverage Successes & Stumbles
      • Mexico: Coverage Successes & Stumbles
    • Key Stakeholders in the Road to Market Access
      • Brazil
      • Mexico
    • Key Market Access Roadblocks
      • Brazil: Key Market Access Roadblocks
      • Mexico: Key Market Access Roadblocks
    • Reimbursement Dynamics
      • Brazil: Coverage Dynamics for Prostate Cancer
        • Brazil: HTA Details and Implications for Drug Coverage
        • Brazil: Drivers of Formulary Coverage
        • Brazil: Coverage & HTA Details
        • Brazil: Lessons Learned and Key Takeaways
        • Brazil: Reimbursement Background
      • Mexico: Coverage Dynamics for Prostate Cancer
        • Mexico: HTA Details and Implications for Drug Coverage
        • Mexico: Drivers of Formulary Coverage
        • Mexico: Coverage Details for Key Prostate Cancer Drugs
        • Mexico: Lessons Learned and Key Takeaways
        • Mexico: Key Background Details of the Healthcare System
    • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
      • Prescriber Practices for Prostate Cancer
        • Prescriber Practices for Non-Metastatic Castration-Resistant Prostate Cancer
      • Prescriber Preferences for Prostate Cancer
      • Impact of Payer Policy on Prescribing for Prostate Cancer
      • Top Prescribing Drivers: Prostate Cancer
      • Key Levers and Constraints on Current Therapies
    • Market Access Landscape for Emerging Therapies
      • Likely Impact of Emerging Therapies on Prostate Cancer
      • Market Access Challenges for Emerging Therapies in Prostate Cancer
      • Payer Opinion on Emerging Therapies for Prostate Cancer
    • Methodology
      • Primary Research Design
      • Physician Demographics and Practice Setting
    • Appendix
      • Commercial Context
        • Epidemiology: Diagnosed Prevalence of Prostate Cancer in Brazil and Mexico
        • Treatment Guidelines for Prostate Cancer in Brazil and Mexico
        • Key Drugs and Drug Classes for Prostate Cancer
        • Price of Treatment with Prostate Cancer Drugs
        • Timeline of Approvals of Key Brands and Emerging Therapies for Prostate Cancer
        • Emerging Therapies Profiles for Non-Metastatic Castrate-Resistant Prostate Cancer
      • Physician Survey Data
        • Prostate Cancer Therapies Reimbursed Under APAC in Brazil
        • Xtandi in Brazil: Reasons for Prescribing to Private First-Line mCRPC Patients
        • Xtandi in Mexico: Reasons for Prescribing to Private First-Line mCRPC Patients
        • Jevtana in Brazil: Reasons for Prescribing to Metastatic Castration-Resistant Prostate Cancer Patients

Already a Client? Log in to access this report.

  • Pub Date: October 2016
  • Author(s): Natalia Reoutova, MSc, MA
  • Natalia Reoutova, , is a senior business insights analyst in the oncology division at Decision Resources Group. Ms. Reoutova has worked on a range of oncology indications including prostate cancer and malignant melanoma. She has authored reports on non-small-cell lung cancer and colorectal cancer, and worked on publications covering both the major and emerging pharmaceutical markets. Natalia Reoutova holds a in natural sciences (specializing in pharmacology) from the University of Cambridge and a in drug discovery from the University of London. Her postgraduate research focused on developing small-molecule inhibitors of oncogenic transcription factors. Prior to working at Decision Resources, she was responsible for planning and estimating the cost of clinical trials at Pharm-Olam International.

Purchase Report

Recent reports:
You may also be interested in: